Last reviewed · How we verify

NCT03934658: NWVRCT

Remote Study of NightWare for PTSD With Nightmares

Completed NA Last updated 28 January 2022
What this trial tests

NA trial testing NightWare Therapeutic System in PostTraumatic Stress Disorder in 81 participants. Completed in 15 December 2021.

Timeline
21 May 2019
Primary endpoint
15 December 2021
15 December 2021

Quick facts

Lead sponsorNightWare
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment81
Start date21 May 2019
Primary completion15 December 2021
Estimated completion15 December 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NightWare

Who can join

18 and older, any sex, with PostTraumatic Stress Disorder or Sleep Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will provide measures of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with the NightWare digital therapeutic system. The investigators hypothesize that the NightWare digital therapeutic system will significantly improve sleep quality in participants with PTSD-Related nightmares and poor sleep quality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of NightWare Therapeutic System

Trials testing the same drug.

Other NightWare trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03934658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing